Lexaria Bioscience Corp.
LEXX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001348362
No open-market purchases or sales by Lexaria Bioscience Corp. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $920.0K in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Lexaria Bioscience Corp. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 25 | 22 | −3 |
| Shares | 1.44M | 1.24M | −201.7K (−14.0%) |
| Value | $3.03M | $2.12M | −$907.2K (−30.0%) |
New holders (2)
Institutions that held Lexaria Bioscience Corp. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Toronto Dominion Bank | 130,025 | $222.4K | 0.00% |
| Federation des caisses Desjardins du Quebec | 382 | $653 | 0.00% |
Sold out (5)
Institutions that held Lexaria Bioscience Corp. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Armistice Capital, LLC | 460,000 | $966.0K |
| Morgan Stanley | 20,229 | $42.5K |
| Scotia Capital Inc. | 10,000 | $21.0K |
| R Squared Ltd | 2,620 | $5.50K |
| UBS Group AG | 116 | $244 |